{"id":161859,"date":"2026-09-08T08:12:07","date_gmt":"2026-09-08T08:12:07","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/161859\/"},"modified":"2026-09-08T08:12:07","modified_gmt":"2026-09-08T08:12:07","slug":"novo-nordisk-falls-2-as-wegovy-opens-a-german-front-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/161859\/","title":{"rendered":"Novo Nordisk Falls 2% as Wegovy Opens a German Front"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This article first appeared on <a href=\"https:\/\/www.gurufocus.com\/news\/9068641\/novo-nordisk-falls-2-as-wegovy-opens-a-german-front?utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;r=caf6fe0e0db70d936033da5461e60141\" data-ylk=\"slk:GuruFocus;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;GuruFocus&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">GuruFocus<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Novo Nordisk (<a href=\"https:\/\/finance.yahoo.com\/quote\/NVO\" data-ylk=\"slk:NYSE%3ANVO;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;NYSE:NVO&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" class=\"stocks_tp\" rel=\"nofollow noopener\">NYSE:NVO<\/a>), the diabetes-and-obesity heavyweight, <a href=\"https:\/\/www.reuters.com\/legal\/litigation\/novo-nordisk-launches-wegovy-weight-loss-pill-germany-2026-09-01\/\" data-ylk=\"slk:fell;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;fell&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">fell<\/a> approximately 2% to $46.625 Friday as Wegovy&#8217;s pill rollout reached its first European Union market. Germany now joins the United States, Britain and the United Arab Emirates in selling the once-daily oral weight-loss treatment.  <\/p>\n<p>        <a href=\"https:\/\/www.gurufocus.com\/term\/gf-value\/NVO?r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_nordisk_falls_2%25_as_wegovy_opens_a_german_front&amp;utm_term=NVO\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novo Nordisk Falls 2% as Wegovy Opens a German Front\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Novo Nordisk Falls 2% as Wegovy Opens a German Front  \u00b7 us.finance.gurufocus         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">German pharmacies are expected to price the pill near Wegovy injections, with doses ranging from roughly 170 to 280. Novo says Wegovy already commands 90% of the oral obesity market and expects tablets to capture more than one-third of GLP-1 usage by 2030. That is the real opportunity: win patients who want weight loss without the needle while protecting revenue per prescription.  <\/p>\n<p>    <a href=\"https:\/\/www.gurufocus.com\/stock\/NVO\/summary?search=nvo&amp;r=9e8553cee17e7be6cdee2cf7b0a937b5&amp;r=caf6fe0e0db70d936033da5461e60141&amp;utm_source=yahoo_finance&amp;utm_medium=syndication&amp;utm_campaign=headlines&amp;utm_content=novo_nordisk_falls_2%25_as_wegovy_opens_a_german_front&amp;utm_term=NVO\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Novo Nordisk Falls 2% as Wegovy Opens a German Front\" height=\"540\" width=\"960\" class=\"yf-1f8hkhu loader\"\/><\/a> Novo Nordisk Falls 2% as Wegovy Opens a German Front  \u00b7 us.finance.gurufocus         <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The valuation picture makes the selloff harder to ignore. Novo&#8217;s $46.625 share price sits 57.51% below its $109.74 GF Value, signaling a steep market discount as investors question whether oral Wegovy can revive growth against Eli Lilly. Germany is now a crucial proving groundstrong prescription uptake and patient retention could turn convenience into Novo&#8217;s next major competitive weapon.  <\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the diabetes-and-obesity heavyweight, fell approximately 2% to $46.625 Friday&hellip;\n","protected":false},"author":2,"featured_media":161860,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[57860,3845,272,3859,1910],"class_list":["post-161859","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-gurufocus","tag-novo","tag-novo-nordisk","tag-nvo","tag-wegovy"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117234418195552515","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=161859"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/161859\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/161860"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=161859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=161859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=161859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}